Structure Therapeutics (NASDAQ:GPCR) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has a $65.00 price target on the stock.

Separately, Lifesci Capital restated an outperform rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of Buy and a consensus price target of $85.71.

Structure Therapeutics Trading Down 2.4 %

Structure Therapeutics stock opened at $36.18 on Thursday. The stock has a 50 day moving average of $40.81 and a 200-day moving average of $48.61. Structure Therapeutics has a 52 week low of $21.79 and a 52 week high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Friday, March 8th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. On average, analysts forecast that Structure Therapeutics will post -0.98 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several large investors have recently added to or reduced their stakes in GPCR. Wellington Management Group LLP increased its position in Structure Therapeutics by 404.0% in the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after buying an additional 3,504,747 shares during the period. Adage Capital Partners GP L.L.C. increased its position in Structure Therapeutics by 835.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company’s stock worth $90,752,000 after buying an additional 1,607,525 shares during the period. Avoro Capital Advisors LLC increased its position in Structure Therapeutics by 133.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after buying an additional 1,333,333 shares during the period. FMR LLC acquired a new stake in Structure Therapeutics in the first quarter worth $29,724,000. Finally, Federated Hermes Inc. increased its position in Structure Therapeutics by 104.2% in the fourth quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock worth $92,411,000 after buying an additional 1,157,006 shares during the period. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.